It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...
Zacks.com on MSN3h
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
Zacks.com on MSN2d
BIIB Secures FDA Nod for Monthly Maintenance Dosing of Alzheimer's DrugThe FDA's approval is based on simulation data from multiple studies showing that maintenance dosing with Biogen???s Leqembi ...
Hosted on MSN1d
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock UpSage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from ...
The stock's fall snapped a five-day winning streak.
Citi analyst Geoff Meacham lowered the firm’s price target on Biogen (BIIB) to $160 from $190 and keeps a Neutral rating on the shares. Ahead ...
24/7 Wall St. on MSN8d
Billionaire Sells Palantir Stock and Buys This Stock That Could Soar 64% According to a Wall Street ExpertThis post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...
Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...
Equities research analysts at Wedbush dropped their FY2024 EPS estimates for Biogen in a research report issued on Thursday, ...
Check the time stamp on this data. Updated AI-Generated Signals for Biogen Inc. (BIIB) available here: BIIB. Type a few ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback